Cytokinetics Inc

Price Chart

Risk-Adjusted Performance

Cytokinetics Inc (CYTK) Price Performance

Cytokinetics Inc (CYTK) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $60.02, down 2.72% from the previous close.

Over the past year, CYTK has traded between a low of $29.84 and a high of $70.10. The stock has gained 37.6% over this period. It is currently 14.4% below its 52-week high.

Cytokinetics Inc has a market capitalization of $7.40B.

About Cytokinetics Inc

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.